Oxaloacetate and fatigue

What 2 graded rows on oxaloacetate agree on for fatigue, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Oxaloacetate page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Oxaloacetate page, with its PubMed record.

Supplement

Oxaloacetate Choose another

2 rows · 201 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade C, is a randomized trial of 82 people (2024) and found an improvement.

The rows run from 82 to 119 people, published from 2022 to 2024: 2 single studies.

2 improved

Grade CFatigue in ME/CFS · Improved
RCT · n 82 · 2024 · Adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
2,000 mg/day · 3 months
Fatigue fell by more than 25% from baseline with oxaloacetate versus a non-significant fall of about 10% with control (between-group p = 0.0039); more people reached a 25% fatigue reduction. Both physical and mental fatigue improved, and it was well tolerated.
Row on the Oxaloacetate page · PubMed 39664752 (opens PubMed)
Grade DPhysical and mental fatigue in ME/CFS and long COVID · Improved
Open-label trial · n 119 · 2022 · Adults with ME/CFS (76; 74% women) or long COVID fatigue for ≥6 months (43)
500 mg twice daily to 1,000 mg three times daily · 6 weeks
ME/CFS fatigue scores fell 22.5–27.9% from baseline (p<0.005), above a 5.9% historical placebo response; long COVID fatigue also fell.
Row on the Oxaloacetate page · PubMed 35764955 (opens PubMed)